IASLC TTLC 2022 | Current challenges in targeting solid tumors with CAR T-cells

Prasad Adusumilli, MD, FACS, Memorial Sloan Kettering Cancer Center, New York, NY, discusses issues in treating solid tumors with chimeric antigen receptor (CAR) T-cell therapy. Compared to hematological malignancies, solid tumors express antigens also found in normal tissue. Administering CAR T-cells may also prove more difficult in solid tumors due to the immunosuppressive tumor microenvironment and T cell exhaustion. However, addition of checkpoint blockades have proven to increase the efficacy of CAR T-cells in solid tumors. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).